Long‐term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open‐label trial

The primary objective of this trial (SP1042; NCT02582866) was to assess long‐term safety and tolerability of lacosamide monotherapy (200‐600 mg/day) in adults with focal (partial‐onset) seizures or generalized tonic‐clonic seizures (without clear focal origin). This Phase III, long‐term, open‐label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben‐Menachem, Elinor, Dominguez, Jacqueline, Szász, József, Beller, Cynthia, Howerton, Charles, Jensen, Lori, McClung, Carrie, Roebling, Robert, Steiniger‐Brach, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408586/
https://www.ncbi.nlm.nih.gov/pubmed/34265173
http://dx.doi.org/10.1002/epi4.12522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408586/
https://www.ncbi.nlm.nih.gov/pubmed/34265173
http://dx.doi.org/10.1002/epi4.12522

Ejemplares similares